-
1
-
-
0032521438
-
Elucidation of the mechanism enabling tumor selective prodrug monotherapy
-
Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M, Monneret C (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58:1195-1201
-
(1998)
Cancer Res
, vol.58
, pp. 1195-1201
-
-
Bosslet, K.1
Straub, R.2
Blumrich, M.3
Czech, J.4
Gerken, M.5
Sperker, B.6
Kroemer, H.K.7
Gesson, J.P.8
Koch, M.9
Monneret, C.10
-
2
-
-
33644994202
-
Vascular targeting: Recent advances and therapeutic perspectives
-
Hajitou A, Pasqualini R, Arap W (2006) Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16:80-88
-
(2006)
Trends Cardiovasc Med
, vol.16
, pp. 80-88
-
-
Hajitou, A.1
Pasqualini, R.2
Arap, W.3
-
3
-
-
0023219734
-
Transport of molecules in the tumor interstitium: A review
-
Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3039-3051
-
(1987)
Cancer Res
, vol.47
, pp. 3039-3051
-
-
Jain, R.K.1
-
4
-
-
0027467414
-
Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability
-
Folli S, Pèlegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F, Mach JP (1993) Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 53:829-836
-
(1993)
Int J Cancer
, vol.53
, pp. 829-836
-
-
Folli, S.1
Pèlegrin, A.2
Chalandon, Y.3
Yao, X.4
Buchegger, F.5
Lienard, D.6
Lejeune, F.7
Mach, J.P.8
-
5
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
6
-
-
0034682892
-
Genes expressed in human tumor endothelium
-
St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197-1202
-
(2000)
Science
, vol.289
, Issue.5482
, pp. 1197-1202
-
-
St. Croix, B.1
Rago, C.2
Velculescu, V.3
Traverso, G.4
Romans, K.E.5
Montgomery, E.6
Lal, A.7
Riggins, G.J.8
Lengauer, C.9
Vogelstein, B.10
Kinzler, K.W.11
-
7
-
-
0035359087
-
Molecular addresses in blood vessels as targets for therapy
-
Kolonin MG, Pasqualini R, Arap W (2001) Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 5:308-313
-
(2001)
Curr Opin Chem Biol
, vol.5
, pp. 308-313
-
-
Kolonin, M.G.1
Pasqualini, R.2
Arap, W.3
-
8
-
-
16844381577
-
A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities
-
Hida K, Klagsburn M (2005) A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65:2507-2510
-
(2005)
Cancer Res
, vol.65
, pp. 2507-2510
-
-
Hida, K.1
Klagsburn, M.2
-
9
-
-
0002501771
-
Antiangiogenic therapy
-
DeVita VT, Hellman S, Rosenberg SA (eds), Lippincott, Philadelphia, PA
-
Folkman J (1997) Antiangiogenic therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, PA, pp 3075-3085
-
(1997)
Cancer: Principles and Practice of Oncology
, pp. 3075-3085
-
-
Folkman, J.1
-
10
-
-
79956328903
-
Molecular mechanisms and clinical applications of angiogenesis
-
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307
-
(2011)
Nature
, vol.473
, pp. 298-307
-
-
Carmeliet, P.1
Jain, R.K.2
-
11
-
-
0013943005
-
Tumour behaviour in isolated perfused organs
-
Folkman J, Cole P, Zimmerman S (1966) Tumour behaviour in isolated perfused organs. Ann Surg 164:491
-
(1966)
Ann Surg
, vol.164
, pp. 491
-
-
Folkman, J.1
Cole, P.2
Zimmerman, S.3
-
12
-
-
0014865863
-
Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumour
-
Tannock IF (1970) Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumour. Cancer Res 30:2470-2477
-
(1970)
Cancer Res
, vol.30
, pp. 2470-2477
-
-
Tannock, I.F.1
-
13
-
-
0028789463
-
Antiangiogenesis as a novel therapeutic concept in pediatric oncology
-
Schweigerer L (1995) Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 73:497-508
-
(1995)
J Mol Med
, vol.73
, pp. 497-508
-
-
Schweigerer, L.1
-
14
-
-
0029551759
-
Microvascular corrosion casting in the study of tumor vascularity: A review
-
Konerding MA, Miodonski AJ, Lametschwandtner A (1995) Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 9:1233-1244
-
(1995)
Scanning Microsc
, vol.9
, pp. 1233-1244
-
-
Konerding, M.A.1
Miodonski, A.J.2
Lametschwandtner, A.3
-
15
-
-
85193187906
-
-
Springer, Berlin
-
Konerding MA, van Ackern C, Fait E, Steinberg F, Streffer C, Molls M, Vaupel P (eds) (2002) Morphological aspects of tumor angiogenesis and microcirculation in blood perfusion and microenvironment of human tumors. Springer, Berlin, pp 5-17
-
(2002)
Morphological Aspects of Tumor Angiogenesis and Microcirculation in Blood Perfusion and Microenvironment of Human Tumors
, pp. 5-17
-
-
Konerding, M.A.1
Van Ackern, C.2
Fait, E.3
Steinberg, F.4
Streffer, C.5
Molls, M.6
Vaupel, P.7
-
17
-
-
33749332105
-
Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature
-
Van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW (2006) Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108(7):2339-2348
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2339-2348
-
-
Van Beijnum, J.R.1
Dings, R.P.2
Van Der Linden, E.3
Zwaans, B.M.4
Ramaekers, F.C.5
Mayo, K.H.6
Griffioen, A.W.7
-
18
-
-
0009504171
-
The vascularization of experimental and human primary tumors: Comparative morphometric and morphologic studies
-
Maragoudakis ME (ed), Plenum, New York
-
Konerding MA, Fait E, Gaumann A, Dimitropoulou C, Malkush W (1998) The vascularization of experimental and human primary tumors: comparative morphometric and morphologic studies. In: Maragoudakis ME (ed) Angiogenesis: models modulators and clinical applications. Plenum, New York, pp 429-447
-
(1998)
Angiogenesis: Models Modulators and Clinical Applications
, pp. 429-447
-
-
Konerding, M.A.1
Fait, E.2
Gaumann, A.3
Dimitropoulou, C.4
Malkush, W.5
-
19
-
-
0032544686
-
Tumor induction of VEGF promoter activity in stromal cells
-
Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-725
-
(1998)
Cell
, vol.94
, pp. 715-725
-
-
Fukumura, D.1
Xavier, R.2
Sugiura, T.3
Chen, Y.4
Park, E.C.5
Lu, N.6
Selig, M.7
Nielsen, G.8
Taksir, T.9
Jain, R.K.10
Seed, B.11
-
20
-
-
0242624629
-
Molecular basis of angiogenesis and cancer
-
Tonini T, Rossi F, Claudio PP (2003) Molecular basis of angiogenesis and cancer. Oncogene 22:6549-6556
-
(2003)
Oncogene
, vol.22
, pp. 6549-6556
-
-
Tonini, T.1
Rossi, F.2
Claudio, P.P.3
-
21
-
-
0034648765
-
Angiogenesis in cancer and other diseases
-
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
-
(2000)
Nature
, vol.407
, pp. 249-257
-
-
Carmeliet, P.1
Jain, R.K.2
-
22
-
-
1442290142
-
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms
-
Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340
-
(2004)
FASEB J
, vol.18
, pp. 338-340
-
-
Erber, R.1
Thurnher, A.2
Katsen, A.D.3
Groth, G.4
Kerger, H.5
Hammes, H.P.6
Menger, M.D.7
Ullrich, A.8
Vajkoczy, P.9
-
23
-
-
0032581277
-
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
-
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490
-
(1998)
Nature
, vol.394
, pp. 485-490
-
-
Carmeliet, P.1
Dor, Y.2
Herbert, J.M.3
Fukumura, D.4
Brusselmans, K.5
Dewerchin, M.6
Neeman, M.7
Bono, F.8
Abramovitch, R.9
Maxwell, P.10
Koch, C.J.11
Ratcliffe, P.12
Moons, L.13
Jain, R.K.14
Collen, D.15
Keshet, E.16
-
24
-
-
0032190614
-
Hypoxia-inducible factor 1: Master regulator of O 2 homeostasis
-
Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O 2 homeostasis. Curr Opin Genet Dev 8:588-594
-
(1998)
Curr Opin Genet Dev
, vol.8
, pp. 588-594
-
-
Semenza, G.L.1
-
25
-
-
0015311426
-
Anti-angiogenesis: New concept for therapy of solid tumors
-
Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175(3):409-416
-
(1972)
Ann Surg
, vol.175
, Issue.3
, pp. 409-416
-
-
Folkman, J.1
-
26
-
-
0030856731
-
Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599
-
(1997)
Cancer Res
, vol.57
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'connor, S.J.3
Chisholm, V.4
Meng, Y.G.5
Krummen, L.6
Winkler, M.7
Ferrara, N.8
-
27
-
-
0032530717
-
VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface
-
Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM (1998) VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6:1153-1167
-
(1998)
Structure
, vol.6
, pp. 1153-1167
-
-
Muller, Y.A.1
Chen, Y.2
Christinger, H.W.3
Li, B.4
Cunningham, B.C.5
Lowman, H.B.6
De Vos, A.M.7
-
28
-
-
13444278498
-
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
-
Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
-
(2005)
Cancer Res
, vol.65
, pp. 671-680
-
-
Gerber, H.P.1
Ferrara, N.2
-
29
-
-
0036831559
-
Vascular and hematopoietic stem cells: Novel targets for anti-angiogenesis therapy?
-
Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and hematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 826-835
-
-
Rafii, S.1
Lyden, D.2
Benezra, R.3
Hattori, K.4
Heissig, B.5
-
30
-
-
0034796595
-
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
-
Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989
-
(2001)
Nat Med
, vol.7
, pp. 987-989
-
-
Jain, R.K.1
-
31
-
-
11844254414
-
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
-
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
-
(2005)
Science
, vol.307
, pp. 58-62
-
-
Jain, R.K.1
-
32
-
-
34748921698
-
Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers
-
Duda DG, Jain RK, Willett CG (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033-4042
-
(2007)
J Clin Oncol
, vol.25
, pp. 4033-4042
-
-
Duda, D.G.1
Jain, R.K.2
Willett, C.G.3
-
33
-
-
79960096827
-
Normalization of the vasculature for treatment of cancer and other diseases
-
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071-1121
-
(2011)
Physiol Rev
, vol.91
, pp. 1071-1121
-
-
Goel, S.1
Duda, D.G.2
Xu, L.3
Munn, L.L.4
Boucher, Y.5
Fukumura, D.6
Jain, R.K.7
-
34
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
-
(2004)
N Engl J Med
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
35
-
-
84857424492
-
-
National cancer institute. Online source, Accessed 10 Oct 2012
-
Pazdur R (2011) FDA approval for Bevacizumab. National cancer institute. Online source: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed 10 Oct 2012
-
(2011)
FDA Approval for Bevacizumab
-
-
Pazdur, R.1
-
36
-
-
10644279947
-
Vascular endothelial growth factor and angiogenesis
-
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56(4):549-580
-
(2004)
Pharmacol Rev
, vol.56
, Issue.4
, pp. 549-580
-
-
Hoeben, A.1
Landuyt, B.2
Highley, M.S.3
Wildiers, H.4
Van Oosterom, A.T.5
De Bruijn, E.A.6
-
37
-
-
0032698140
-
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
-
Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209
-
(1999)
Cancer Res
, vol.59
, pp. 5209
-
-
Prewett, M.1
Huber, J.2
Li, Y.3
Santiago, A.4
O'connor, W.5
King, K.6
Overholser, J.7
Hooper, A.8
Pytowski, B.9
Witte, L.10
Bohlen, P.11
Hicklin, D.J.12
-
38
-
-
0035884609
-
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2
-
Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624
-
(2001)
Cancer Res
, vol.61
, pp. 6624
-
-
Kunkel, P.1
Ulbricht, U.2
Bohlen, P.3
Brockmann, M.A.4
Fillbrandt, R.5
Stavrou, D.6
Westphal, M.7
Lamszus, K.8
-
39
-
-
0036023438
-
Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production
-
Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8(8):2714-2724
-
(2002)
Clin Cancer Res
, vol.8
, Issue.8
, pp. 2714-2724
-
-
Sweeney, P.1
Karashima, T.2
Kim, S.J.3
Kedar, D.4
Mian, B.5
Huang, S.6
Baker, C.7
Fan, Z.8
Hicklin, D.J.9
Pettaway, C.A.10
Dinney, C.P.11
-
40
-
-
79955795408
-
A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM)
-
Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Fox FE, Schwartz JD, Bedikian AY (2010) A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). J Clin Oncol 28:15
-
(2010)
J Clin Oncol
, vol.28
, pp. 15
-
-
Carvajal, R.D.1
Wong, M.K.2
Thompson, J.A.3
Gordon, M.S.4
Lewis, K.D.5
Pavlick, A.C.6
Wolchok, J.D.7
Fox, F.E.8
Schwartz, J.D.9
Bedikian, A.Y.10
-
41
-
-
84860254547
-
A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
-
Zhu AX, Finn RS, Mulcahy MF, Gurtler JS, Sun W, Schwartz JD, Rojas P, Dontabhaktuni A, Youssoufian H, Stuart KE (2010) A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 28:15
-
(2010)
J Clin Oncol
, vol.28
, pp. 15
-
-
Zhu, A.X.1
Finn, R.S.2
Mulcahy, M.F.3
Gurtler, J.S.4
Sun, W.5
Schwartz, J.D.6
Rojas, P.7
Dontabhaktuni, A.8
Youssoufian, H.9
Stuart, K.E.10
-
42
-
-
85193159780
-
-
Accessed 19 Oct 2012
-
UCB press statement: 01.04.2008: http://www.bionity.com/en/news/80262/ucb-phase-iiresults-for-cdp791-in-non-small-cell-lung-cancer-support-further-clinical-development.html. Accessed 19 Oct 2012
-
UCB Press Statement: 01.04.2008
-
-
-
43
-
-
0037143764
-
VEGF-Trap: A VEGF blocker with potent antitumor effects
-
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 11393-11398
-
-
Holash, J.1
Davis, S.2
Papadopoulos, N.3
Croll, S.D.4
Ho, L.5
Russell, M.6
Boland, P.7
Leidich, R.8
Hylton, D.9
Burova, E.10
Ioffe, E.11
Huang, T.12
Radziejewski, C.13
Bailey, K.14
Fandl, J.P.15
Daly, T.16
Wiegand, S.J.17
Yancopoulos, G.D.18
Rudge, J.S.19
-
44
-
-
0037401890
-
VEGF-TrapR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier
-
Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA (2003) VEGF-TrapR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241-248
-
(2003)
J Cell Physiol
, vol.195
, pp. 241-248
-
-
Saishin, Y.1
Saishin, Y.2
Takahashi, K.3
Lima Silva, E.R.4
Hylton, D.5
Rudge, J.S.6
Wiegand, S.J.7
Campochiaro, P.A.8
-
45
-
-
84866370357
-
Aflibercept for age-related macular degeneration: A game-changer or quiet addition?
-
Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154(2):222-226
-
(2012)
Am J Ophthalmol
, vol.154
, Issue.2
, pp. 222-226
-
-
Browning, D.J.1
Kaiser, P.K.2
Rosenfeld, P.J.3
Stewart, M.W.4
-
46
-
-
84867602821
-
Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: A randomized, controlled phase III trial
-
Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G (2012) Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 30(29):3640-3647
-
(2012)
J Clin Oncol
, vol.30
, Issue.29
, pp. 3640-3647
-
-
Ramlau, R.1
Gorbunova, V.2
Ciuleanu, T.E.3
Novello, S.4
Ozguroglu, M.5
Goksel, T.6
Baldotto, C.7
Bennouna, J.8
Shepherd, F.A.9
Le-Guennec, S.10
Rey, A.11
Miller, V.12
Thatcher, N.13
Scagliotti, G.14
-
47
-
-
84863011440
-
Aflibercept in the treatment of metastatic colorectal cancer
-
Wang TF, Lockhart AC (2012) Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 6:19-30
-
(2012)
Clin Med Insights Oncol
, vol.6
, pp. 19-30
-
-
Wang, T.F.1
Lockhart, A.C.2
-
48
-
-
84867047384
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
-
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499-3506
-
(2012)
J Clin Oncol
, vol.30
, Issue.28
, pp. 3499-3506
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
Prenen, H.4
Prausová, J.5
Macarulla, T.6
Ruff, P.7
Van Hazel, G.A.8
Moiseyenko, V.9
Ferry, D.10
McKendrick, J.11
Polikoff, J.12
Tellier, A.13
Castan, R.14
Allegra, C.15
-
49
-
-
33845867080
-
Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice
-
Kumar R, Harrington LE, Hopper TM, Miller CG, Onori JA, Cheung M, Stafford JA, Epperly AH, Gilmer TM (2005) Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. J Clin Oncol. ASCO Annual Meeting Proceedings 23(16):9537
-
(2005)
J Clin Oncol. ASCO Annual Meeting Proceedings
, vol.23
, Issue.16
, pp. 9537
-
-
Kumar, R.1
Harrington, L.E.2
Hopper, T.M.3
Miller, C.G.4
Onori, J.A.5
Cheung, M.6
Stafford, J.A.7
Epperly, A.H.8
Gilmer, T.M.9
-
50
-
-
33846149645
-
AZD2171, a pan-veGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
-
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-veGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95
-
(2007)
Cancer Cell
, vol.11
, pp. 83-95
-
-
Batchelor, T.T.1
Sorensen, A.G.2
Di Tomaso, E.3
Zhang, W.T.4
Duda, D.G.5
Cohen, K.S.6
Kozak, K.R.7
Cahill, D.P.8
Chen, P.J.9
Zhu, M.10
Ancukiewicz, M.11
Mrugala, M.M.12
Plotkin, S.13
Drappatz, J.14
Louis, D.N.15
Ivy, P.16
Scadden, D.T.17
Benner, T.18
Loeffler, J.S.19
Wen, P.Y.20
Jain, R.K.21
more..
-
51
-
-
38949178751
-
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KrN951 in a rat peritoneal disseminated tumor model
-
Taguchi E, Nakamura K, Miura T, Shibuya M, Isoe T (2008) Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KrN951 in a rat peritoneal disseminated tumor model. Cancer Sci 99:623-630
-
(2008)
Cancer Sci
, vol.99
, pp. 623-630
-
-
Taguchi, E.1
Nakamura, K.2
Miura, T.3
Shibuya, M.4
Isoe, T.5
-
52
-
-
79551521053
-
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C08
-
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C08. J Clin Oncol 29:11-16
-
(2011)
J Clin Oncol
, vol.29
, pp. 11-16
-
-
Allegra, C.J.1
Yothers, G.2
O'connell, M.J.3
Sharif, S.4
Petrelli, N.J.5
Colangelo, L.H.6
Atkins, J.N.7
Seay, T.E.8
Fehrenbacher, L.9
Goldberg, R.M.10
O'reilly, S.11
Chu, L.12
Azar, C.A.13
Lopa, S.14
Wolmark, N.15
-
53
-
-
79953236184
-
AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer
-
De Gramont A, Van Cutsem E, Tabernero J, Moore MJ, Cunningham D, Rivera F, Im S, Makrutzki M, Shang A, Hoff PM (2011) AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 29(4):362
-
(2011)
J Clin Oncol
, vol.29
, Issue.4
, pp. 362
-
-
De Gramont, A.1
Van Cutsem, E.2
Tabernero, J.3
Moore, M.J.4
Cunningham, D.5
Rivera, F.6
Im, S.7
Makrutzki, M.8
Shang, A.9
Hoff, P.M.10
-
54
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
55
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.L.1
Lee, C.R.2
Cruz-Munoz, W.3
Bjarnason, G.A.4
Christensen, J.G.5
Kerbel, R.S.6
-
56
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Pàez-Ribes, M.1
Allen, E.2
Hudock, J.3
Takeda, T.4
Okuyama, H.5
Viñals, F.6
Inoue, M.7
Bergers, G.8
Hanahan, D.9
Casanovas, O.10
-
57
-
-
35648941728
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan- refractory colorectal cancer: The BOND-2 study
-
Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan- refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557-4561
-
(2007)
J Clin Oncol
, vol.25
, pp. 4557-4561
-
-
Saltz, L.B.1
Lenz, H.J.2
Kindler, H.L.3
Hochster, H.S.4
Wadler, S.5
Hoff, P.M.6
Kemeny, N.E.7
Hollywood, E.M.8
Gonen, M.9
Quinones, M.10
Morse, M.11
Chen, H.X.12
-
58
-
-
39749166386
-
Antiangiogenic therapy for cancer: An update
-
Shojaei F, Ferrara N (2007) Antiangiogenic therapy for cancer: an update. Cancer J 13:345-348
-
(2007)
Cancer J
, vol.13
, pp. 345-348
-
-
Shojaei, F.1
Ferrara, N.2
-
59
-
-
35548941394
-
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC)
-
Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol 25:4508
-
(2007)
J Clin Oncol
, vol.25
, pp. 4508
-
-
Kindler, H.L.1
Niedzwiecki, D.2
Hollis, D.3
Oraefo, E.4
Schrag, D.5
Hurwitz McLeod, H.L.6
Mulcahy, M.F.7
Schilsky, R.L.8
Goldberg, R.M.9
-
60
-
-
0035692285
-
Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches
-
Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J (2001) Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 20:79-86
-
(2001)
Cancer Metastasis Rev
, vol.20
, pp. 79-86
-
-
Kerbel, R.S.1
Yu, J.2
Tran, J.3
Man, S.4
Viloria-Petit, A.5
Klement, G.6
Coomber, B.L.7
Rak, J.8
-
61
-
-
26644471951
-
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
-
Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309
-
(2005)
Cancer Cell
, vol.8
, pp. 299-309
-
-
Casanovas, O.1
Hicklin, D.J.2
Bergers, G.3
Hanahan, D.4
-
62
-
-
80051690789
-
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition
-
Allen E, Walters IB, Hanahan D (2011) Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5299
-
-
Allen, E.1
Walters, I.B.2
Hanahan, D.3
-
63
-
-
24744438663
-
Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells
-
Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, Zimmer MA, Iliopoulos O, Zukerberg LR, Kohgo Y, Lynch MP, Rueda BR, Chung DC (2005) Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat Med 11:992-997
-
(2005)
Nat Med
, vol.11
, pp. 992-997
-
-
Mizukami, Y.1
Jo, W.S.2
Duerr, E.M.3
Gala, M.4
Li, J.5
Zhang, X.6
Zimmer, M.A.7
Iliopoulos, O.8
Zukerberg, L.R.9
Kohgo, Y.10
Lynch, M.P.11
Rueda, B.R.12
Chung, D.C.13
-
64
-
-
40949148520
-
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors
-
Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS (2008) Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14:1529-1539
-
(2008)
Clin Cancer Res
, vol.14
, pp. 1529-1539
-
-
Fernando, N.T.1
Koch, M.2
Rothrock, C.3
Gollogly, L.K.4
D'amore, P.A.5
Ryeom, S.6
Yoon, S.S.7
-
65
-
-
0036344496
-
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
-
Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P III, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MAS, Werb Z, Lyden D, Rafii S (2002) Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat Med 8:841-849
-
(2002)
Nat Med
, vol.8
, pp. 841-849
-
-
Hattori, K.1
Heissig, B.2
Wu, Y.3
Dias, S.4
Tejada, R.5
Ferris, B.6
Hicklin, D.J.7
Zhu, Z.8
Bohlen Iii, P.9
Witte, L.10
Hendrikx, J.11
Hackett, N.R.12
Crystal, R.G.13
Moore, M.A.S.14
Werb, Z.15
Lyden, D.16
Rafii, S.17
-
66
-
-
28644432204
-
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
-
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827
-
(2005)
Nature
, vol.438
, pp. 820-827
-
-
Kaplan, R.N.1
Riba, R.D.2
Zacharoulis, S.3
Bramley, A.H.4
Vincent, L.5
Costa, C.6
Macdonald, D.D.7
Jin, D.K.8
Shido, K.9
Kerns, S.A.10
Zhu, Z.11
Hicklin, D.12
Wu, Y.13
Port, J.L.14
Altorki, N.15
Port, E.R.16
Ruggero, D.17
Shmelkov, S.V.18
Jensen, K.K.19
Rafii, S.20
Lyden, D.21
more..
-
67
-
-
0038476608
-
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
-
Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295
-
(2003)
J Clin Invest
, vol.111
, pp. 1287-1295
-
-
Bergers, G.1
Song, S.2
Meyer-Morse, N.3
Bergsland, E.4
Hanahan, D.5
-
68
-
-
0346727319
-
What brings pericytes to tumor vessels?
-
Jain RK, Booth MF (2003) What brings pericytes to tumor vessels? J Clin Invest 112:1134-1136
-
(2003)
J Clin Invest
, vol.112
, pp. 1134-1136
-
-
Jain, R.K.1
Booth, M.F.2
-
69
-
-
0031834239
-
A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
-
Benjamin L, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598
-
(1998)
Development
, vol.125
, pp. 1591-1598
-
-
Benjamin, L.1
Hemo, I.2
Keshet, E.3
-
70
-
-
0033822622
-
Anti- VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
-
Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti- VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314
-
(2000)
Neoplasia
, vol.2
, pp. 306-314
-
-
Rubenstein, J.L.1
Kim, J.2
Ozawa, T.3
Zhang, M.4
Westphal, M.5
Deen, D.F.6
Shuman, M.A.7
-
71
-
-
0041382820
-
The hypoxic response of tumors is dependent on their microenvironment
-
Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4:133-146
-
(2003)
Cancer Cell
, vol.4
, pp. 133-146
-
-
Blouw, B.1
Song, H.2
Tihan, T.3
Bosze, J.4
Ferrara, N.5
Gerber, H.P.6
Johnson, R.S.7
Bergers, G.8
-
72
-
-
39849102836
-
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
-
Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, VandenBerg S, Johnson RS, Werb Z, Bergers G (2008) HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-220
-
(2008)
Cancer Cell
, vol.13
, pp. 206-220
-
-
Du, R.1
Lu, K.V.2
Petritsch, C.3
Liu, P.4
Ganss, R.5
Passegué, E.6
Song, H.7
Vandenberg, S.8
Johnson, R.S.9
Werb, Z.10
Bergers, G.11
-
73
-
-
41649112610
-
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
-
Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
-
(2008)
Neurology
, vol.70
, pp. 779-787
-
-
Norden, A.D.1
Young, G.S.2
Setayesh, K.3
Muzikansky, A.4
Klufas, R.5
Ross, G.L.6
Ciampa, A.S.7
Ebbeling, L.G.8
Levy, B.9
Drappatz, J.10
Kesari, S.11
Wen, P.Y.12
-
74
-
-
60649116273
-
Anti-angiogenic therapy using bevacizumab in recurrent high grade glioma: Impact on local control and survival
-
Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML (2009) Anti-angiogenic therapy using bevacizumab in recurrent high grade glioma: impact on local control and survival. J Neurosurg 110(1):173-180
-
(2009)
J Neurosurg
, vol.110
, Issue.1
, pp. 173-180
-
-
Narayana, A.1
Kelly, P.2
Golfinos, J.3
Parker, E.4
Johnson, G.5
Knopp, E.6
Zagzag, D.7
Fischer, I.8
Raza, S.9
Medabalmi, P.10
Eagan, P.11
Gruber, M.L.12
-
75
-
-
68049139572
-
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells
-
Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15:4838
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4838
-
-
Xiong, Y.Q.1
Sun, H.C.2
Zhang, W.3
Zhu, X.D.4
Zhuang, P.Y.5
Zhang, J.B.6
Wang, L.7
Wu, W.Z.8
Qin, L.X.9
Tang, Z.Y.10
-
76
-
-
67650380136
-
Biomarkers of response and resistance to antiangiogenic therapy
-
Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6):327-338
-
(2009)
Nat Rev Clin Oncol
, vol.6
, Issue.6
, pp. 327-338
-
-
Jain, R.K.1
Duda, D.G.2
Willett, C.G.3
Sahani, D.V.4
Zhu, A.X.5
Loeffler, J.S.6
Batchelor, T.T.7
Sorensen, A.G.8
-
77
-
-
77950679333
-
Can animal models of disease reliably inform human studies?
-
van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7(3):e1000245
-
(2010)
PLoS Med
, vol.7
, Issue.3
, pp. e1000245
-
-
Van Der Worp, H.B.1
Howells, D.W.2
Sena, E.S.3
Porritt, M.J.4
Rewell, S.5
O'collins, V.6
Macleod, M.R.7
-
78
-
-
84857995039
-
Predictive in vivo animal models and translation to clinical trials
-
Cook N, Jodrell DI, Tuveson DA (2012) Predictive in vivo animal models and translation to clinical trials. Drug Discov Today 17(5-6):253-260
-
(2012)
Drug Discov Today
, vol.17
, Issue.5-6
, pp. 253-260
-
-
Cook, N.1
Jodrell, D.I.2
Tuveson, D.A.3
-
80
-
-
0000742387
-
A critique of tumour resistance
-
Woglam WH (1923) A critique of tumour resistance. J Cancer Res 7:283-311
-
(1923)
J Cancer Res
, vol.7
, pp. 283-311
-
-
Woglam, W.H.1
-
82
-
-
0020081554
-
Endothelial cell proliferation as a novel approach to targeting tumour therapy
-
Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-139
-
(1982)
Br J Cancer
, vol.45
, pp. 136-139
-
-
Denekamp, J.1
-
83
-
-
0020449692
-
Endothelial-cell proliferation in experimental tumours
-
Denekamp J, Hobson B (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46(5):711-720
-
(1982)
Br J Cancer
, vol.46
, Issue.5
, pp. 711-720
-
-
Denekamp, J.1
Hobson, B.2
-
84
-
-
0025093973
-
Vascular attack as a therapeutic strategy for cancer
-
Denekamp J (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9:267-282
-
(1990)
Cancer Metastasis Rev
, vol.9
, pp. 267-282
-
-
Denekamp, J.1
-
85
-
-
0033395393
-
Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumour therapy
-
Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K, Sato Y (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumour therapy. Jpn J Cancer Res 90:1387-1396
-
(1999)
Jpn J Cancer Res
, vol.90
, pp. 1387-1396
-
-
Nihei, Y.1
Suzuki, M.2
Okano, A.3
Tsuji, T.4
Akiyama, Y.5
Tsuruo, T.6
Saito, S.7
Hori, K.8
Sato, Y.9
-
86
-
-
0025793698
-
Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
-
Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482-487
-
(1991)
Eur J Cancer
, vol.27
, pp. 482-487
-
-
Baguley, B.C.1
Holdaway, K.M.2
Thomsen, L.L.3
Zhuang, L.4
Zwi, L.J.5
-
87
-
-
0030951899
-
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature
-
Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57:1829-1834
-
(1997)
Cancer Res
, vol.57
, pp. 1829-1834
-
-
Dark, G.G.1
Hill, S.A.2
Prise, V.E.3
Tozer, G.M.4
Pettit, G.R.5
Chaplin, D.J.6
-
88
-
-
0031748452
-
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
-
Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77:1761-1767
-
(1998)
Br J Cancer
, vol.77
, pp. 1761-1767
-
-
Beauregard, D.A.1
Thelwall, P.E.2
Chaplin, D.J.3
Hill, S.A.4
Adams, G.E.5
Brindle, K.M.6
-
89
-
-
0031770618
-
The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
-
Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J (1998) The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42(4):895-898
-
(1998)
Int J Radiat Oncol Biol Phys
, vol.42
, Issue.4
, pp. 895-898
-
-
Horsman, M.R.1
Ehrnrooth, E.2
Ladekarl, M.3
Overgaard, J.4
-
90
-
-
0034906627
-
Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model
-
Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE (2001) Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7(4):1052-1060
-
(2001)
Clin Cancer Res
, vol.7
, Issue.4
, pp. 1052-1060
-
-
Malcontenti-Wilson, C.1
Muralidharan, V.2
Skinner, S.3
Christophi, C.4
Sherris, D.5
O'brien, P.E.6
-
91
-
-
0033119771
-
Combretastatin A-4 phosphate as a tumour vascular targeting agent: Early effects in tumours and normal tissues
-
Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumour vascular targeting agent: early effects in tumours and normal tissues. Cancer Res 59:1626-1634
-
(1999)
Cancer Res
, vol.59
, pp. 1626-1634
-
-
Tozer, G.M.1
Prise, V.E.2
Wilson, J.3
Locke, R.J.4
Vojnovic, B.5
Stratford, M.R.6
Dennis, M.F.7
Chaplin, D.J.8
-
92
-
-
84860183520
-
A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial
-
Sosa JA, Elisei R, Jarzab B, Bal CS, Koussis H, Gramza AW, Ben-Yosef R, Gitlitz BJ, Haugen B, Karandikar SM, Khuri FR, Licitra LF, Remick SC, Marur S, Lu C, Ondrey FG, Lu S, Balkissoon J (2011) A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. J Clin Oncol 29:2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011
-
-
Sosa, J.A.1
Elisei, R.2
Jarzab, B.3
Bal, C.S.4
Koussis, H.5
Gramza, A.W.6
Ben-Yosef, R.7
Gitlitz, B.J.8
Haugen, B.9
Karandikar, S.M.10
Khuri, F.R.11
Licitra, L.F.12
Remick, S.C.13
Marur, S.14
Lu, C.15
Ondrey, F.G.16
Lu, S.17
Balkissoon, J.18
-
93
-
-
0036253091
-
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours
-
Holwell SE, Cooper PA, Grosios K, Lippert JW III, Pettit GR, Shnyder SD, Bibby MC (2002) Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res 22:707-711
-
(2002)
Anticancer Res
, vol.22
, pp. 707-711
-
-
Holwell, S.E.1
Cooper, P.A.2
Grosios, K.3
Lippert Iii, J.W.4
Pettit, G.R.5
Shnyder, S.D.6
Bibby, M.C.7
-
94
-
-
84857692454
-
Phase i clinical and pharmacokinetic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors
-
Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MRL, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani A, Rustin GJS (2012) Phase I clinical and pharmacokinetic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 18(5):1415-1425
-
(2012)
Clin Cancer Res
, vol.18
, Issue.5
, pp. 1415-1425
-
-
Patterson, D.M.1
Zweifel, M.2
Middleton, M.R.3
Price, P.M.4
Folkes, L.K.5
Stratford, M.R.L.6
Ross, P.7
Halford, S.8
Peters, J.9
Balkissoon, J.10
Chaplin, D.J.11
Padhani, A.12
Rustin, G.J.S.13
-
95
-
-
77956324472
-
Leukemia regression by vascular disruption and antiangiogenic therapy
-
Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR (2010) Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 116:1539-1547
-
(2010)
Blood
, vol.116
, pp. 1539-1547
-
-
Madlambayan, G.J.1
Meacham, A.M.2
Hosaka, K.3
Mir, S.4
Jorgensen, M.5
Scott, E.W.6
Siemann, D.W.7
Cogle, C.R.8
-
96
-
-
0032734864
-
A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
-
Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T (1999) A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 90(9):1016-1025
-
(1999)
Jpn J Cancer Res
, vol.90
, Issue.9
, pp. 1016-1025
-
-
Nihei, Y.1
Suga, Y.2
Morinaga, Y.3
Ohishi, K.4
Okano, A.5
Ohsumi, K.6
Hatanaka, T.7
Nakagawa, R.8
Tsuji, T.9
Akiyama, Y.10
Saito, S.11
Hori, K.12
Sato, Y.13
Tsuruo, T.14
-
97
-
-
0032729686
-
Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700
-
Hori K, Saito S, Nihei Y, Suzuki M, Sato Y (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038
-
(1999)
Jpn J Cancer Res
, vol.90
, pp. 1026-1038
-
-
Hori, K.1
Saito, S.2
Nihei, Y.3
Suzuki, M.4
Sato, Y.5
-
98
-
-
0035146174
-
Stoppage of blood flow in 3-methylcholanthreneinduced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect
-
Hori K, Saito S, Sato Y, Kubota K (2001) Stoppage of blood flow in 3-methylcholanthreneinduced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 7:26-33
-
(2001)
Med Sci Monit
, vol.7
, pp. 26-33
-
-
Hori, K.1
Saito, S.2
Sato, Y.3
Kubota, K.4
-
99
-
-
0037141466
-
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
-
Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86:1604-1614
-
(2002)
Br J Cancer
, vol.86
, pp. 1604-1614
-
-
Hori, K.1
Saito, S.2
Kubota, K.3
-
100
-
-
0035985910
-
Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer
-
Ohno T, Kawano K, Sasaki A, Aramaki M, Tahara K, Etoh T, Kitano S (2002) Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int J Clin Oncol 7:171-176
-
(2002)
Int J Clin Oncol
, vol.7
, pp. 171-176
-
-
Ohno, T.1
Kawano, K.2
Sasaki, A.3
Aramaki, M.4
Tahara, K.5
Etoh, T.6
Kitano, S.7
-
101
-
-
84879554909
-
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
-
Clémenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E (2012) The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 31(2):273-284
-
(2012)
Invest New Drugs
, vol.31
, Issue.2
, pp. 273-284
-
-
Clémenson, C.1
Jouannot, E.2
Merino-Trigo, A.3
Rubin-Carrez, C.4
Deutsch, E.5
-
102
-
-
0034530967
-
Cadherins as modulators of angiogenesis and the structural integrity of blood vessels
-
Blaschuk OW, Rowlands TM (2000) Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev 19:1-5
-
(2000)
Cancer Metastasis Rev
, vol.19
, pp. 1-5
-
-
Blaschuk, O.W.1
Rowlands, T.M.2
-
104
-
-
33947302866
-
Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization
-
Kelland L (2007) Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization. Curr Opin Mol Ther 9:86-91
-
(2007)
Curr Opin Mol Ther
, vol.9
, pp. 86-91
-
-
Kelland, L.1
-
105
-
-
34247096609
-
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer
-
Li H, Price DK, Figg WD (2007) ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs 18:563-568
-
(2007)
Anticancer Drugs
, vol.18
, pp. 563-568
-
-
Li, H.1
Price, D.K.2
Figg, W.D.3
-
107
-
-
63549149565
-
Clinical and pharmacological phase i evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours
-
Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L (2009) Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 20:741-745
-
(2009)
Ann Oncol
, vol.20
, pp. 741-745
-
-
Perotti, A.1
Sessa, C.2
Mancuso, A.3
Noberasco, C.4
Cresta, S.5
Locatelli, A.6
Carcangiu, M.L.7
Passera, K.8
Braghetti, A.9
Scaramuzza, D.10
Zanaboni, F.11
Fasolo, A.12
Capri, G.13
Miani, M.14
Peters, W.P.15
Gianni, L.16
-
108
-
-
84873134086
-
Phase i clinical trial of Exherin (ADH-1) in patients with advanced solid tumors
-
Yarom N, Stewart D, Malik R, Wells J, Avruch L, Jonker DJ (2012) Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors. Curr Clin Pharmacol 8(1):81-88
-
(2012)
Curr Clin Pharmacol
, vol.8
, Issue.1
, pp. 81-88
-
-
Yarom, N.1
Stewart, D.2
Malik, R.3
Wells, J.4
Avruch, L.5
Jonker, D.J.6
-
109
-
-
0036278972
-
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models
-
Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1974-1983
-
-
Blakey, D.C.1
Westwood, F.R.2
Walker, M.3
Hughes, G.D.4
Davis, P.D.5
Ashton, S.E.6
Ryan, A.J.7
-
110
-
-
0037112419
-
High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow
-
Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS (2002) High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62:6371-6375
-
(2002)
Cancer Res
, vol.62
, pp. 6371-6375
-
-
Goertz, D.E.1
Yu, J.L.2
Kerbel, R.S.3
Burns, P.N.4
Foster, F.S.5
-
111
-
-
0037115398
-
ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature
-
Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253
-
(2002)
Cancer Res
, vol.62
, pp. 7247-7253
-
-
Davis, P.D.1
Dougherty, G.J.2
Blakey, D.C.3
Galbraith, S.M.4
Tozer, G.M.5
Holder, A.L.6
Naylor, M.A.7
Nolan, J.8
Stratford, M.R.9
Chaplin, D.J.10
Hill, S.A.11
-
112
-
-
0036891109
-
Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126
-
Siemann DW, Rojiani AM (2002) Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54:1512-1517
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.54
, pp. 1512-1517
-
-
Siemann, D.W.1
Rojiani, A.M.2
-
113
-
-
0036644835
-
Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice
-
Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S (2002) Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 62:3711-3715
-
(2002)
Cancer Res
, vol.62
, pp. 3711-3715
-
-
Goto, H.1
Yano, S.2
Zhang, H.3
Matsumori, Y.4
Ogawa, H.5
Blakey, D.C.6
Sone, S.7
-
114
-
-
33845286942
-
Vascular disrupting agents
-
Lippert JW III (2007) Vascular disrupting agents. Bioorg Med Chem 15(2):605-615
-
(2007)
Bioorg Med Chem
, vol.15
, Issue.2
, pp. 605-615
-
-
Lippert Iii, J.W.1
-
115
-
-
38449099577
-
Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats
-
Gould S, Westwood FR, Curwen JO, Ashton SE, Roberts DW, Lovick SC, Ryan AJ (2007) Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 99:1724-1728
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 1724-1728
-
-
Gould, S.1
Westwood, F.R.2
Curwen, J.O.3
Ashton, S.E.4
Roberts, D.W.5
Lovick, S.C.6
Ryan, A.J.7
-
116
-
-
0842311621
-
Vascular targeting agents as cancer therapeutics
-
Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427
-
(2004)
Clin Cancer Res
, vol.10
, pp. 415-427
-
-
Thorpe, P.E.1
-
117
-
-
0027368441
-
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature
-
Burrows FJ, Thorpe PE (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90:8996-9000
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 8996-9000
-
-
Burrows, F.J.1
Thorpe, P.E.2
-
118
-
-
0024594936
-
A tumorassociated fibronectin isoform generated by alternative splicing of messenger RNA precursors
-
Carnemolla B, Baiza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natalie PG (1989) A tumorassociated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 108:1139-1148
-
(1989)
J Cell Biol
, vol.108
, pp. 1139-1148
-
-
Carnemolla, B.1
Baiza, E.2
Siri, A.3
Zardi, L.4
Nicotra, M.R.5
Bigotti, A.6
Natalie, P.G.7
-
119
-
-
0029802551
-
Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain
-
Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 68(3):397-405
-
(1996)
Int J Cancer
, vol.68
, Issue.3
, pp. 397-405
-
-
Carnemolla, B.1
Neri, D.2
Castellani, P.3
Leprini, A.4
Neri, G.5
Pini, A.6
Winter, G.7
Zardi, L.8
-
120
-
-
0036841992
-
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin
-
Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 161(5):1695-1700
-
(2002)
Am J Pathol
, vol.161
, Issue.5
, pp. 1695-1700
-
-
Castellani, P.1
Borsi, L.2
Carnemolla, B.3
Birò, A.4
Dorcaratto, A.5
Viale, G.L.6
Neri, D.7
Zardi, L.8
-
121
-
-
0030700632
-
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
-
Neri D, Carnemolla B, Nissim A, Leprini A, Querzè G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15(12):1271-1275
-
(1997)
Nat Biotechnol
, vol.15
, Issue.12
, pp. 1271-1275
-
-
Neri, D.1
Carnemolla, B.2
Nissim, A.3
Leprini, A.4
Querzè, G.5
Balza, E.6
Pini, A.7
Tarli, L.8
Halin, C.9
Neri, P.10
Zardi, L.11
Winter, G.12
-
122
-
-
0037827261
-
Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors
-
Birchler MT, Milisavlijevic D, Pfaltz M, Neri D, Odermatt B, Schmid S, Stoeckli SJ (2003) Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 113(7):1231-1237
-
(2003)
Laryngoscope
, vol.113
, Issue.7
, pp. 1231-1237
-
-
Birchler, M.T.1
Milisavlijevic, D.2
Pfaltz, M.3
Neri, D.4
Odermatt, B.5
Schmid, S.6
Stoeckli, S.J.7
-
123
-
-
70249129332
-
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma
-
Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33(12):1718-1722
-
(2009)
Leuk Res
, vol.33
, Issue.12
, pp. 1718-1722
-
-
Schliemann, C.1
Wiedmer, A.2
Pedretti, M.3
Szczepanowski, M.4
Klapper, W.5
Neri, D.6
-
124
-
-
63849261384
-
Expression of the oncofetal ED-Bcontaining fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
-
Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD (2009) Expression of the oncofetal ED-Bcontaining fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113:2265-2274
-
(2009)
Blood
, vol.113
, pp. 2265-2274
-
-
Sauer, S.1
Erba, P.A.2
Petrini, M.3
Menrad, A.4
Giovannoni, L.5
Grana, C.6
Hirsch, B.7
Zardi, L.8
Paganelli, G.9
Mariani, G.10
Neri, D.11
Dürkop, H.12
Menssen, H.D.13
-
125
-
-
0036603896
-
In vivo phage display and vascular heterogeneity: Implications for targeted medicine
-
Trepel M, Arap W, Pasqualini R (2002) In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 6:399-404
-
(2002)
Curr Opin Chem Biol
, vol.6
, pp. 399-404
-
-
Trepel, M.1
Arap, W.2
Pasqualini, R.3
-
126
-
-
18244407799
-
Steps toward mapping the human vasculature by phage display
-
Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8:121-127
-
(2002)
Nat Med
, vol.8
, pp. 121-127
-
-
Arap, W.1
Kolonin, M.G.2
Trepel, M.3
Lahdenranta, J.4
Cardo-Vila, M.5
Giordano, R.J.6
Mintz, P.J.7
Ardelt, P.U.8
Yao, V.J.9
Vidal, C.I.10
Chen, L.11
Flamm, A.12
Valtanen, H.13
Weavind, L.M.14
Hicks, M.E.15
Pollock, R.E.16
Botz, G.H.17
Bucana, C.D.18
Koivunen, E.19
Cahill, D.20
Troncoso, P.21
Baggerly, K.A.22
Pentz, R.D.23
Do, K.A.24
Logothetis, C.J.25
Pasqualini, R.26
more..
-
127
-
-
0037133279
-
Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature
-
Essler M, Ruoslahti E (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A 99(4):2252-2257
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, Issue.4
, pp. 2252-2257
-
-
Essler, M.1
Ruoslahti, E.2
-
128
-
-
33846014642
-
Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection
-
Ruan W, Sassoon A, An F, Simko JP, Liu B (2006) Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics 5(12):2364-2373
-
(2006)
Mol Cell Proteomics
, vol.5
, Issue.12
, pp. 2364-2373
-
-
Ruan, W.1
Sassoon, A.2
An, F.3
Simko, J.P.4
Liu, B.5
-
129
-
-
1942424256
-
Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries
-
Mutuberria R, Satijn S, Huijbers A, Van Der Linden E, Lichtenbeld H, Chames P, Arends JW, Hoogenboom HR (2004) Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Methods 287(1-2):31-47
-
(2004)
J Immunol Methods
, vol.287
, Issue.1-2
, pp. 31-47
-
-
Mutuberria, R.1
Satijn, S.2
Huijbers, A.3
Van Der Linden, E.4
Lichtenbeld, H.5
Chames, P.6
Arends, J.W.7
Hoogenboom, H.R.8
-
130
-
-
0035884593
-
Cell surface tumor endothelial markers are conserved in mice and humans
-
Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St. Croix B (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61:6649-6655
-
(2001)
Cancer Res
, vol.61
, pp. 6649-6655
-
-
Carson-Walter, E.B.1
Watkins, D.N.2
Nanda, A.3
Vogelstein, B.4
Kinzler, K.W.5
St. Croix, B.6
-
131
-
-
0000403288
-
Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays
-
Zhang HT, Gorn M, Smith K, Graham AP, Lau KK, Bicknell R (1999) Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis 3(3):211-219
-
(1999)
Angiogenesis
, vol.3
, Issue.3
, pp. 211-219
-
-
Zhang, H.T.1
Gorn, M.2
Smith, K.3
Graham, A.P.4
Lau, K.K.5
Bicknell, R.6
-
132
-
-
0038387504
-
Identification of endothelial cell genes by combined database mining and microarray analysis
-
Ho M, Yang E, Matcuk G, Deng D, Sampas N, Tsalenko A, Tabibiazar R, Zhang Y, Chen M, Talbi S, Ho YD, Wang J, Tsao PS, Ben-Dor A, Yakhini Z, Bruhn L, Quertermous T (2003) Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol Genomics 13(3):249-262
-
(2003)
Physiol Genomics
, vol.13
, Issue.3
, pp. 249-262
-
-
Ho, M.1
Yang, E.2
Matcuk, G.3
Deng, D.4
Sampas, N.5
Tsalenko, A.6
Tabibiazar, R.7
Zhang, Y.8
Chen, M.9
Talbi, S.10
Ho, Y.D.11
Wang, J.12
Tsao, P.S.13
Ben-Dor, A.14
Yakhini, Z.15
Bruhn, L.16
Quertermous, T.17
-
133
-
-
44649110229
-
Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium
-
Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani MR (2008) Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 9:201
-
(2008)
BMC Genomics
, vol.9
, pp. 201
-
-
Ghilardi, C.1
Chiorino, G.2
Dossi, R.3
Nagy, Z.4
Giavazzi, R.5
Bani, M.R.6
-
134
-
-
0033669849
-
In silico cloning of novel endothelial-specific genes
-
Huminiecki L, Bicknell R (2000) In silico cloning of novel endothelial-specific genes. Genome Res 10(11):1796-1806
-
(2000)
Genome Res
, vol.10
, Issue.11
, pp. 1796-1806
-
-
Huminiecki, L.1
Bicknell, R.2
-
135
-
-
0036209165
-
Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis
-
Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R (2002) Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79(4):547-552
-
(2002)
Genomics
, vol.79
, Issue.4
, pp. 547-552
-
-
Huminiecki, L.1
Gorn, M.2
Suchting, S.3
Poulsom, R.4
Bicknell, R.5
-
136
-
-
0344443678
-
EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor
-
Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulsom R, Creamer D, Barker J, Bicknell R (2003) EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem 278:47079-47088
-
(2003)
J Biol Chem
, vol.278
, pp. 47079-47088
-
-
Sullivan, D.C.1
Huminiecki, L.2
Moore, J.W.3
Boyle, J.J.4
Poulsom, R.5
Creamer, D.6
Barker, J.7
Bicknell, R.8
-
137
-
-
42949106096
-
A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes
-
Herbert JMJ, Stekel D, Sanderson S, Heath VL, Bicknell R (2008) A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics 9:153
-
(2008)
BMC Genomics
, vol.9
, pp. 153
-
-
Herbert, J.M.J.1
Stekel, D.2
Sanderson, S.3
Heath, V.L.4
Bicknell, R.5
-
138
-
-
2942529235
-
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy
-
Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429(6992):629-635
-
(2004)
Nature
, vol.429
, Issue.6992
, pp. 629-635
-
-
Oh, P.1
Li, Y.2
Yu, J.3
Durr, E.4
Krasinska, K.M.5
Carver, L.A.6
Testa, J.E.7
Schnitzer, J.E.8
-
139
-
-
18744399322
-
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature
-
Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2(4):291-298
-
(2005)
Nat Methods
, vol.2
, Issue.4
, pp. 291-298
-
-
Rybak, J.N.1
Ettorre, A.2
Kaissling, B.3
Giavazzi, R.4
Neri, D.5
Elia, G.6
-
140
-
-
33751416666
-
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer
-
Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, Neri D (2006) A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 5(11):2083-2091
-
(2006)
Mol Cell Proteomics
, vol.5
, Issue.11
, pp. 2083-2091
-
-
Castronovo, V.1
Waltregny, D.2
Kischel, P.3
Roesli, C.4
Elia, G.5
Rybak, J.N.6
Neri, D.7
-
141
-
-
57349106602
-
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis
-
Conrotto P, Roesli C, Rybak J, Kischel P, Waltregny D, Neri D, Castronovo V (2008) Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 123(12):2856-2864
-
(2008)
Int J Cancer
, vol.123
, Issue.12
, pp. 2856-2864
-
-
Conrotto, P.1
Roesli, C.2
Rybak, J.3
Kischel, P.4
Waltregny, D.5
Neri, D.6
Castronovo, V.7
-
142
-
-
0029611184
-
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy
-
Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1:1623-1634
-
(1995)
Clin Cancer Res
, vol.1
, pp. 1623-1634
-
-
Burrows, F.J.1
Derbyshire, E.J.2
Tazzari, P.L.3
Amlot, P.4
Gazdar, A.F.5
King, S.W.6
Letarte, M.7
Vitetta, E.S.8
Thorpe, P.E.9
-
143
-
-
0031026481
-
Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
-
Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547-550
-
(1997)
Science
, vol.275
, pp. 547-550
-
-
Huang, X.1
Molema, G.2
King, S.3
Watkins, L.4
Edgington, T.S.5
Thorpe, P.E.6
-
144
-
-
0032532656
-
Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature
-
Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE (1998) Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58:4646-4653
-
(1998)
Cancer Res
, vol.58
, pp. 4646-4653
-
-
Ran, S.1
Gao, B.2
Duffy, S.3
Watkins, L.4
Rote, N.5
Thorpe, P.E.6
-
145
-
-
0035863566
-
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice
-
Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:711-716
-
(2001)
Cancer Res
, vol.61
, pp. 711-716
-
-
Nilsson, F.1
Kosmehl, H.2
Zardi, L.3
Neri, D.4
-
146
-
-
0036791157
-
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors
-
Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, Edgington TS (2002) Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62:5470-5475
-
(2002)
Cancer Res
, vol.62
, pp. 5470-5475
-
-
Liu, C.1
Huang, H.2
Donate, F.3
Dickinson, C.4
Santucci, R.5
El-Sheikh, A.6
Vessella, R.7
Edgington, T.S.8
-
147
-
-
0032943892
-
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
-
Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59:183-188
-
(1999)
Cancer Res
, vol.59
, pp. 183-188
-
-
Arora, N.1
Masood, R.2
Zheng, T.3
Cai, J.4
Smith, D.L.5
Gill, P.S.6
-
148
-
-
0029915612
-
Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
-
Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D (1996) Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56:1324-1330
-
(1996)
Cancer Res
, vol.56
, pp. 1324-1330
-
-
Ramakrishnan, S.1
Olson, T.A.2
Bautch, V.L.3
Mohanraj, D.4
-
149
-
-
0037062464
-
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors
-
Veenendaal LM, Jin H, Cheung L, Ran S, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG (2002) In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 99:7866-7871
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 7866-7871
-
-
Veenendaal, L.M.1
Jin, H.2
Cheung, L.3
Ran, S.4
Navone, N.5
Marks, J.W.6
Waltenberger, J.7
Thorpe, P.8
Rosenblum, M.G.9
-
150
-
-
0036493867
-
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
-
Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5):1659-1665
-
(2002)
Blood
, vol.99
, Issue.5
, pp. 1659-1665
-
-
Carnemolla, B.1
Borsi, L.2
Balza, E.3
Castellani, P.4
Meazza, R.5
Berndt, A.6
Ferrini, S.7
Kosmehl, H.8
Neri, D.9
Zardi, L.10
-
151
-
-
33748866249
-
An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties
-
Gafner V, Trachsel E, Neri D (2006) An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 119(9):2205-2212
-
(2006)
Int J Cancer
, vol.119
, Issue.9
, pp. 2205-2212
-
-
Gafner, V.1
Trachsel, E.2
Neri, D.3
-
152
-
-
42549099073
-
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
-
Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rösli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11):2405-2413
-
(2008)
Int J Cancer
, vol.122
, Issue.11
, pp. 2405-2413
-
-
Villa, A.1
Trachsel, E.2
Kaspar, M.3
Schliemann, C.4
Sommavilla, R.5
Rybak, J.N.6
Rösli, C.7
Borsi, L.8
Neri, D.9
-
153
-
-
0037404842
-
Endoglin (CD105): A target for antiangiogenetic cancer therapy
-
Fonsatti E, Altomonte M, Arslan P, Maio M (2003) Endoglin (CD105): a target for antiangiogenetic cancer therapy. Curr Drug Targets 4(4):291-296
-
(2003)
Curr Drug Targets
, vol.4
, Issue.4
, pp. 291-296
-
-
Fonsatti, E.1
Altomonte, M.2
Arslan, P.3
Maio, M.4
-
154
-
-
33744811140
-
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C
-
Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12(10):3200-3208
-
(2006)
Clin Cancer Res
, vol.12
, Issue.10
, pp. 3200-3208
-
-
Brack, S.S.1
Silacci, M.2
Birchler, M.3
Neri, D.4
-
155
-
-
37649010802
-
Clinical experience with alpha-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
-
Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD (2007) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49(1):30-38
-
(2007)
J Nucl Med
, vol.49
, Issue.1
, pp. 30-38
-
-
Zalutsky, M.R.1
Reardon, D.A.2
Akabani, G.3
Coleman, R.E.4
Friedman, A.H.5
Friedman, H.S.6
McLendon, R.E.7
Wong, T.Z.8
Bigner, D.D.9
-
156
-
-
0032712235
-
Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: A novel drug carrier for cancer targeting therapy
-
Tsunoda S, Ohizumi I, Matsui J, Koizumi K, Wakai Y, Makimoto H, Tsutsumi Y, Utoguchi N, Taniguchi K, Saito H, Harada N, Ohsugi Y, Mayumi T (1999) Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy. Br J Cancer 81:1155-1161
-
(1999)
Br J Cancer
, vol.81
, pp. 1155-1161
-
-
Tsunoda, S.1
Ohizumi, I.2
Matsui, J.3
Koizumi, K.4
Wakai, Y.5
Makimoto, H.6
Tsutsumi, Y.7
Utoguchi, N.8
Taniguchi, K.9
Saito, H.10
Harada, N.11
Ohsugi, Y.12
Mayumi, T.13
-
157
-
-
0032842567
-
Tumor targeting with a selective gelatinase inhibitor
-
Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkilä P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768-774
-
(1999)
Nat Biotechnol
, vol.17
, pp. 768-774
-
-
Koivunen, E.1
Arap, W.2
Valtanen, H.3
Rainisalo, A.4
Medina, O.P.5
Heikkilä, P.6
Kantor, C.7
Gahmberg, C.G.8
Salo, T.9
Konttinen, Y.T.10
Sorsa, T.11
Ruoslahti, E.12
Pasqualini, R.13
-
158
-
-
57749090308
-
Integrin αvβ3-targeted cancer therapy
-
Liu Z, Wang F, Chen X (2008) Integrin αvβ3-targeted cancer therapy. Drug Dev Res 69(6):329-339
-
(2008)
Drug Dev Res
, vol.69
, Issue.6
, pp. 329-339
-
-
Liu, Z.1
Wang, F.2
Chen, X.3
-
159
-
-
0141919559
-
E-selectin upregulation allows for targeted drug delivery in prostate cancer
-
Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DE, Ramakrishnan V (2003) E-selectin upregulation allows for targeted drug delivery in prostate cancer. Cancer Res 63:6387-6394
-
(2003)
Cancer Res
, vol.63
, pp. 6387-6394
-
-
Bhaskar, V.1
Law, D.A.2
Ibsen, E.3
Breinberg, D.4
Cass, K.M.5
Dubridge, R.B.6
Evangelista, F.7
Henshall, S.M.8
Hevezi, P.9
Miller, J.C.10
Pong, M.11
Powers, R.12
Senter, P.13
Stockett, D.14
Sutherland, R.L.15
Von Freeden-Jeffry, U.16
Willhite, D.17
Murray, R.18
Afar, D.E.19
Ramakrishnan, V.20
more..
-
160
-
-
78650868374
-
Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion
-
Rho SS, Choi HJ, Min JK, Lee HW, Park H, Park H, Kim YM, Kwon YG (2011) Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion. Biochem Biophys Res Commun 404(1):103-108
-
(2011)
Biochem Biophys Res Commun
, vol.404
, Issue.1
, pp. 103-108
-
-
Rho, S.S.1
Choi, H.J.2
Min, J.K.3
Lee, H.W.4
Park, H.5
Park, H.6
Kim, Y.M.7
Kwon, Y.G.8
-
161
-
-
14644430393
-
Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice
-
Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE (2005) Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 11:1551-1562
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1551-1562
-
-
Ran, S.1
He, J.2
Huang, X.3
Soares, M.4
Scothorn, D.5
Thorpe, P.E.6
-
162
-
-
0033529314
-
Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model
-
Hu Z, Sun Y, Garen A (1999) Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A 96(14):8161-8166
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, Issue.14
, pp. 8161-8166
-
-
Hu, Z.1
Sun, Y.2
Garen, A.3
-
163
-
-
77649185057
-
Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies
-
Zhang YF, Wang J, Bian D, Zhang X, Zhang Q (2010) Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 74(3):467-473
-
(2010)
Eur J Pharm Biopharm
, vol.74
, Issue.3
, pp. 467-473
-
-
Zhang, Y.F.1
Wang, J.2
Bian, D.3
Zhang, X.4
Zhang, Q.5
-
165
-
-
14944353793
-
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs
-
Corti A, Ponzoni M (2004) Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 1028:104-112
-
(2004)
Ann N y Acad Sci
, vol.1028
, pp. 104-112
-
-
Corti, A.1
Ponzoni, M.2
-
166
-
-
0038124364
-
Targeted delivery of mutant Raf kinase to neovessels causes tumor regression
-
Hood JD, Cheresh DA (2002) Targeted delivery of mutant Raf kinase to neovessels causes tumor regression. Cold Spring Harb Symp Quant Biol 67:285-292
-
(2002)
Cold Spring Harb Symp Quant Biol
, vol.67
, pp. 285-292
-
-
Hood, J.D.1
Cheresh, D.A.2
-
167
-
-
0037022366
-
Targeting the prostate for destruction through a vascular address
-
Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E (2002) Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 99(3):1527-1531
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, Issue.3
, pp. 1527-1531
-
-
Arap, W.1
Haedicke, W.2
Bernasconi, M.3
Kain, R.4
Rajotte, D.5
Krajewski, S.6
Ellerby, H.M.7
Bredesen, D.E.8
Pasqualini, R.9
Ruoslahti, E.10
-
168
-
-
33747122052
-
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature
-
Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA (2006) Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47(7):1127-1135
-
(2006)
J Nucl Med
, vol.47
, Issue.7
, pp. 1127-1135
-
-
Tijink, B.M.1
Neri, D.2
Leemans, C.R.3
Budde, M.4
Dinkelborg, L.M.5
Stigter-Van Walsum, M.6
Zardi, L.7
Van Dongen, G.A.8
-
169
-
-
0033624570
-
Evaluation of 225 Ac for vascular targeted radioimmunotherapy of lung tumors
-
Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, Davis A, Stabin M, Mirzadeh S (2000) Evaluation of 225 Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother Radiopharm 15(3):235-244
-
(2000)
Cancer Biother Radiopharm
, vol.15
, Issue.3
, pp. 235-244
-
-
Kennel, S.J.1
Chappell, L.L.2
Dadachova, K.3
Brechbiel, M.W.4
Lankford, T.K.5
Davis, A.6
Stabin, M.7
Mirzadeh, S.8
-
170
-
-
0032697129
-
Radioimmunotherapy using vascular targeted 213Bi: The role of tumor necrosis factor alpha in the development of pulmonary fibrosis
-
Davis IA, Kennel SJ (1999) Radioimmunotherapy using vascular targeted 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis. Clin Cancer Res 5(10):3160-3164
-
(1999)
Clin Cancer Res
, vol.5
, Issue.10
, pp. 3160-3164
-
-
Davis, I.A.1
Kennel, S.J.2
-
171
-
-
74049132050
-
First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT-phase II study
-
Löhr M, Haas S, Bechstein W, Karrasch M, Mescheder A, Meyer I, Bodoky G, Pap A, Jäger D, Fölsch UR (2008) First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT-phase II study. J Clin Oncol 26:2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 2008
-
-
Löhr, M.1
Haas, S.2
Bechstein, W.3
Karrasch, M.4
Mescheder, A.5
Meyer, I.6
Bodoky, G.7
Pap, A.8
Jäger, D.9
Fölsch, U.R.10
-
172
-
-
85193166823
-
-
Accessed 2 Oct 2012
-
Medigene press statement: http://www.medigene.com/products-pipeline/developmentprojects/endotag-1. Accessed 2 Oct 2012
-
Medigene Press Statement
-
-
-
173
-
-
51049100187
-
The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer
-
Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A (2008) The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 14(15):4951-4960
-
(2008)
Clin Cancer Res
, vol.14
, Issue.15
, pp. 4951-4960
-
-
Wagner, K.1
Schulz, P.2
Scholz, A.3
Wiedenmann, B.4
Menrad, A.5
-
174
-
-
67650079943
-
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma
-
Johannsen M, Roemer A, Spitaleri G, Curigliano G, Giovannoni L, Menssen HD, Zardi L, Neri D, Miller K, de Braud FG (2008) Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma. J Clin Oncol 26:2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 2008
-
-
Johannsen, M.1
Roemer, A.2
Spitaleri, G.3
Curigliano, G.4
Giovannoni, L.5
Menssen, H.D.6
Zardi, L.7
Neri, D.8
Miller, K.9
De Braud, F.G.10
-
175
-
-
84929675680
-
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients
-
Garbe C, Romanini A, Spitaleri G, Giovannoni L, Zardi L, Neri D, Shaw A, Menssen HD, deBraud F, Eigentler TK (2009) Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients. J Clin Oncol 27:15s
-
(2009)
J Clin Oncol
, vol.27
, pp. 15s
-
-
Garbe, C.1
Romanini, A.2
Spitaleri, G.3
Giovannoni, L.4
Zardi, L.5
Neri, D.6
Shaw, A.7
Menssen, H.D.8
DeBraud, F.9
Eigentler, T.K.10
-
176
-
-
84918804807
-
Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients
-
Weide B, Eigentler TK, Romanini A, De Braud FG, Giovannoni L, Neri D, Menssen H, Garbe C (2010) Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients. J Clin Oncol 28:15s
-
(2010)
J Clin Oncol
, vol.28
, pp. 15s
-
-
Weide, B.1
Eigentler, T.K.2
Romanini, A.3
De Braud, F.G.4
Giovannoni, L.5
Neri, D.6
Menssen, H.7
Garbe, C.8
-
177
-
-
0035488968
-
Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors
-
Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P, Hall FL (2001) Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. Int J Mol Med 8:335-343
-
(2001)
Int J Mol Med
, vol.8
, pp. 335-343
-
-
Masood, R.1
Gordon, E.M.2
Whitley, M.D.3
Wu, B.W.4
Cannon, P.5
Evans, L.6
Anderson, W.F.7
Gill, P.8
Hall, F.L.9
-
178
-
-
80052399280
-
Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy
-
Yao X, Yoshioka Y, Morishige T, Eto Y, Narimatsu S, Kawai Y, Mizuguchi H, Gao JQ, Mukai Y, Okada N, Nakagawa S (2011) Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol Ther 19(9):1619-1625
-
(2011)
Mol Ther
, vol.19
, Issue.9
, pp. 1619-1625
-
-
Yao, X.1
Yoshioka, Y.2
Morishige, T.3
Eto, Y.4
Narimatsu, S.5
Kawai, Y.6
Mizuguchi, H.7
Gao, J.Q.8
Mukai, Y.9
Okada, N.10
Nakagawa, S.11
-
179
-
-
0036204508
-
Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene
-
Jin N, Chen W, Blazar BR, Ramakrishnan S, Vallera DA (2002) Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene. Hum Gene Ther 13:497-508
-
(2002)
Hum Gene Ther
, vol.13
, pp. 497-508
-
-
Jin, N.1
Chen, W.2
Blazar, B.R.3
Ramakrishnan, S.4
Vallera, D.A.5
-
180
-
-
84864812720
-
Antiangiogenic tumor therapy by DNA vaccine inducing aquaporin-1-specific CTL based on ubiquitin-proteasome system in mice
-
Chou B, Hiromatsu K, Okano S, Ishii K, Duan X, Sakai T, Murata S, Tanaka K, Himeno K (2012) Antiangiogenic tumor therapy by DNA vaccine inducing aquaporin-1-specific CTL based on ubiquitin-proteasome system in mice. J Immunol 189(4):1618-1626
-
(2012)
J Immunol
, vol.189
, Issue.4
, pp. 1618-1626
-
-
Chou, B.1
Hiromatsu, K.2
Okano, S.3
Ishii, K.4
Duan, X.5
Sakai, T.6
Murata, S.7
Tanaka, K.8
Himeno, K.9
-
181
-
-
2642571660
-
Vascular-targeting therapies for treatment of malignant disease
-
Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100(12):2491-2499
-
(2004)
Cancer
, vol.100
, Issue.12
, pp. 2491-2499
-
-
Siemann, D.W.1
Chaplin, D.J.2
Horsman, M.R.3
-
182
-
-
1842689545
-
Targeting the tumor vasculature: A strategy to improve radiation therapy
-
Siemann DW, Horsman MR (2004) Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev Anticancer Ther 4(2):321-327
-
(2004)
Expert Rev Anticancer Ther
, vol.4
, Issue.2
, pp. 321-327
-
-
Siemann, D.W.1
Horsman, M.R.2
-
183
-
-
14644446018
-
A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
-
Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23(5):939-952
-
(2005)
J Clin Oncol
, vol.23
, Issue.5
, pp. 939-952
-
-
Pietras, K.1
Hanahan, D.2
-
184
-
-
67651166780
-
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
-
Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8(7):1867-1877
-
(2009)
Mol Cancer Ther
, vol.8
, Issue.7
, pp. 1867-1877
-
-
Rapisarda, A.1
Hollingshead, M.2
Uranchimeg, B.3
Bonomi, C.A.4
Borgel, S.D.5
Carter, J.P.6
Gehrs, B.7
Raffeld, M.8
Kinders, R.J.9
Parchment, R.10
Anver, M.R.11
Shoemaker, R.H.12
Melillo, G.13
-
185
-
-
0033881435
-
Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma
-
Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60(15):4066-4069
-
(2000)
Cancer Res
, vol.60
, Issue.15
, pp. 4066-4069
-
-
Ferrario, A.1
Von Tiehl, K.F.2
Rucker, N.3
Schwarz, M.A.4
Gill, P.S.5
Gomer, C.J.6
-
186
-
-
7444259131
-
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
-
Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60(4):1233-1240
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.60
, Issue.4
, pp. 1233-1240
-
-
Siemann, D.W.1
Shi, W.2
-
187
-
-
27744553032
-
Targeting the tumor vasculature: Enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474
-
Shi W, Siemann DW (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19(6):1045-1050
-
(2005)
Vivo
, vol.19
, Issue.6
, pp. 1045-1050
-
-
Shi, W.1
Siemann, D.W.2
-
188
-
-
49049086508
-
Dual targeting of tumor vasculature: Combining Avastin and vascular disrupting agents (CA4P or OXi4503
-
Siemann DW, Shi W (2008) Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 28(4B):2027-2031
-
(2008)
Anticancer Res
, vol.28 B
, Issue.4
, pp. 2027-2031
-
-
Siemann, D.W.1
Shi, W.2
-
189
-
-
60749109735
-
A phase i study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
-
Nathan PD, Judson I, Padhani A, Harris A, Carden CP, Smythe J, Collins D, Leach M, Walicke P, Rustin GJ (2008) A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26:3550
-
(2008)
J Clin Oncol
, vol.26
, pp. 3550
-
-
Nathan, P.D.1
Judson, I.2
Padhani, A.3
Harris, A.4
Carden, C.P.5
Smythe, J.6
Collins, D.7
Leach, M.8
Walicke, P.9
Rustin, G.J.10
-
190
-
-
84859606443
-
A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial
-
Garon EB, Kabbinavar FF, Neidhart JA, Neidhart JD, Gabrail NY, Oliveira MR, Lu S, Balkissoon J (2011) A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial. J Clin Oncol 29:2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011
-
-
Garon, E.B.1
Kabbinavar, F.F.2
Neidhart, J.A.3
Neidhart, J.D.4
Gabrail, N.Y.5
Oliveira, M.R.6
Lu, S.7
Balkissoon, J.8
-
191
-
-
0031016945
-
Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6- dimethylxanthenone-4-acetic acid
-
Pruijn FB, van Daalen M, Holford NH, Wilson WR (1997) Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6- dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39(6):541-546
-
(1997)
Cancer Chemother Pharmacol
, vol.39
, Issue.6
, pp. 541-546
-
-
Pruijn, F.B.1
Van Daalen, M.2
Holford, N.H.3
Wilson, W.R.4
|